 |
NELATIMOTIDE AND ADEGRAMOTIDE combination |
|---|---|
| Trade Name | |
| Orphan Indication | Myelodysplastic syndrome |
| USA Market Approval | USA |
| USA Designation Date | 2017-06-19 00:00:00 |
| Sponsor | Boston Biomedical, Inc.;640 Memorial Drive;Cambridge, Massachusetts, 02139 |
| |
NELATIMOTIDE AND ADEGRAMOTIDE combination |
|---|---|
| Trade Name | |
| Orphan Indication | Myelodysplastic syndrome |
| USA Market Approval | USA |
| USA Designation Date | 2017-06-19 00:00:00 |
| Sponsor | Boston Biomedical, Inc.;640 Memorial Drive;Cambridge, Massachusetts, 02139 |